Black Diamond Therapeutics (BDTX) Stock
Precision oncology company developing targeted cancer treatments. Here's the price, business snapshot, and what's worth knowing about Black Diamond Therapeutics in July 2026.
Black Diamond Therapeutics (BDTX) is a clinical-stage precision oncology company focused on discovering and developing small-molecule therapies that target oncogenic drivers. The company uses a targeted discovery approach to identify patients whose tumours are driven by specific genetic alterations, aiming for therapies that can offer more selective activity and potentially improved tolerability versus non-targeted treatments. As a smaller-cap biotechnology firm (market cap approximately $225M), progress depends heavily on clinical trial results, regulatory feedback and partnership opportunities. Financial resources, trial enrolment and competitive developments can materially affect prospects. For investors, Black Diamond represents an opportunity-play in precision oncology with asymmetric outcomes: successful trials could materially re-rate the stock, while setbacks could produce significant share volatility. This summary is for educational purposes only and not investment advice; returns are not guaranteed and investors should consider their risk tolerance and seek independent advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Black Diamond Therapeutics stock, expecting it to rise significantly in value.
Financial Health
Black Diamond Therapeutics is producing strong cash flow and has a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring BDTX
Biotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
Published: 17 November 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Precision oncology focus
BDTX targets treatments to tumours with specific genetic drivers, which can improve selectivity — though clinical proof is required and outcomes vary.
Clinical catalysts ahead
Trial readouts and regulatory steps can drive sharp share moves, creating opportunity but also heightening volatility and uncertainty.
Funding and competition
Smaller biotechs depend on capital, partnerships and competitive landscape; these factors can materially affect prospects and share performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
